• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Vanishing Twin Pregnancy: Outcomes with IVF-ICSI vs Natural Conception

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Vanishing twin is a relatively common occurrence in pregnancies conceived with IVF, while natural occurrence is less well known  
  • Márton et al. (Fertil Steril 2016) evaluated whether there is a difference between vanishing twin pregnancy outcome following IVF-ICSI compared to natural conception  

METHODS: 

  • Longitudinal, retrospective cohort study (1994-2014) 
  • Vanishing twin cases were matched to singleton controls 
  • Monochorionic twins were excluded  
  • Vanishing twin diagnosis <14 weeks 
    • Two viable embryos with cardiac activity with spontaneous reduction of one embryo or  
    • Single viable embryo and an additional gestational sac established  
  • Primary outcome was obstetric and neonatal outcome data 
  • Data adjusted for  
    • Maternal Age | Parity | Chronic maternal diseases | Obstetric history data  

RESULTS: 

  • 65,237 singleton deliveries were identified 
    • 1,563 twins, of which 306 vanishing twins 
    • Vanishing twin rate: 4.69/1000  
    • There were 78 IVF-ICSI vanishing twin cases and 228 natural conception vanishing twin cases   
  • The incidence of a embryonic/fetal loss <14 weeks was higher after natural conception (18.2%) than after IVF-ICSI (12.6%); P=0.002
  • 5.2% of singleton deliveries that originated from a pregnancy where vanishing twin was noted followed ART vs 0.37% after a spontaneous pregnancy
  • In IVF-ICSI vanishing twin pregnancies, when compared to matched controls  
    • Gestational diabetes risk was increased; adjusted odds ratio (aOR) 0.80 (natural) vs 3.10 (IVF-ICSI) 
    • Pregestational diabetes risk was increased: aOR 1.00 (natural) vs 1.07 (IVF-ICSI) 
    • Retained placenta: aOR 0.67 (natural) vs 7.2 (IVF-ICSI) 
  • IUGR risk increased in both IVF-ICSI and spontaneous vanishing twin 
    • IVF–ICSI: aOR 9.2; 95% CI, 5-22  
    • Spontaneous conception: aOR 3.0; 95% CI, 1.8-5.2 
  • Risk for vanishing twin in a spontaneous conception was increased with  
    • Previous induced abortion: aOR 1.34 
    • Second-trimester fetal loss: aOR 3.3 
  • Risk factors for vanishing twin following IVF-ICSI  
    • Gestational diabetes mellitus in previous pregnancy: aOR 5.41 
    • Gestational diabetes in current pregnancy: aOR 2.3  
    • Chronic maternal diseases: aOR 3.5 
  • No associations found with preeclampsia or preterm birth

CONCLUSION: 

  • Vanishing twin pregnancies had a lower prevalence but worse perinatal outcome after IVF-ICSI, compared to natural conception 
    • Lower occurrence of a vanishing twin in ART pregnancies is likely due to selection against abnormal embryos during the IVF-ICSI procedure
  • Vanishing twin appears to be an independent risk factor for adverse perinatal outcomes  
    • Vanishing twin may “induce growth restriction in the remaining twin”  
  • Risk factors for vanishing twin suggests that adverse outcomes may correlate with maternal/infertility background rather than the ART procedure

Learn More – Primary Sources:  

Prevalences and pregnancy outcome of vanishing twin pregnancies achieved by in vitro fertilization versus natural conception

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ASRM guidance: ART and recommended number of embryos to transfer
Are Offspring of IVF/ICSI Pregnancies at Higher Risk for Congenital Heart Defects?
Does ART Increase Risk of Postpartum Hemorrhage?
Infertility Treatment and Childhood Development

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site